MX2011013901A - Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k. - Google Patents
Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.Info
- Publication number
- MX2011013901A MX2011013901A MX2011013901A MX2011013901A MX2011013901A MX 2011013901 A MX2011013901 A MX 2011013901A MX 2011013901 A MX2011013901 A MX 2011013901A MX 2011013901 A MX2011013901 A MX 2011013901A MX 2011013901 A MX2011013901 A MX 2011013901A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammatory
- disorders
- myelo
- restricted
- diseases
- Prior art date
Links
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- NYJWYCAHJRGKMI-UHFFFAOYSA-N pyrido[1,2-a]pyrimidin-4-one Chemical class C1=CC=CN2C(=O)C=CN=C21 NYJWYCAHJRGKMI-UHFFFAOYSA-N 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 abstract 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 101001024630 Drosophila melanogaster RNA cytidine acetyltransferase Proteins 0.000 abstract 1
- 101000652705 Drosophila melanogaster Transcription initiation factor TFIID subunit 4 Proteins 0.000 abstract 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 abstract 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 101000996915 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleoporin NSP1 Proteins 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 abstract 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 abstract 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C07D473/38—Sulfur atom attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se exponen heteroarilos bicíclicos sustituidos y las composiciones que los contienen, para el tratamiento de la inflamación general, artritis, enfermedades reumáticas, osteoartrosis, trastornos inflamatorios del intestino, trastornos inflamatorios del ojo, trastornos inflamatorios de la vejiga o vejiga inestable, psoriasis, enfermedades cutáneas con componentes inflamatorios, condiciones inflamatorias crónicas, entre las que se incluyen de manera enunciativa, enfermedades autoinmunes tales como lupus eritematoso sistémico (SLE), miastenia grave, artritis reumatoide, encefalomielitis diseminada aguda, púrpura trombocitopénica idiopática, esclerosis múltiple, síndrome de Sjoegren y anemia hemolítica autoinmune, condiciones alérgicas, entre las que se incluyen todas las formas de hipersensibilidad, la presente invención también abarca métodos para el tratamiento de cánceres que se producen, dependen o están asociados con la actividad de p110, incluyendo de manera enunciativa leucemias, tales como, leucemia mieloide aguda (AML) síndrome mielo-displásico (MDS), enfermedades mielo-proliferativas (MPD) leucemia mieloide crónica (CML), leucemia linfoblástica aguda de células T (T-ALL) leucemia linfoblástica aguda de células B (NB-ALL) leucemia que no es de Hodgkins (NHL) linfoma de células B y tumores sólidos, tales como cáncer de mama.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22048409P | 2009-06-25 | 2009-06-25 | |
| PCT/US2010/039931 WO2010151735A2 (en) | 2009-06-25 | 2010-06-25 | Heterocyclic compounds and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011013901A true MX2011013901A (es) | 2012-05-08 |
Family
ID=42753363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011013901A MX2011013901A (es) | 2009-06-25 | 2010-06-25 | Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8754089B2 (es) |
| EP (1) | EP2445898A2 (es) |
| JP (1) | JP2012531435A (es) |
| AU (1) | AU2010266064A1 (es) |
| CA (1) | CA2765817A1 (es) |
| MX (1) | MX2011013901A (es) |
| WO (1) | WO2010151735A2 (es) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009260447B2 (en) | 2008-05-30 | 2012-03-29 | Amgen Inc. | Inhibitors of PI3 kinase |
| CA2766100C (en) | 2009-06-29 | 2018-05-22 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| SG193982A1 (en) | 2011-03-28 | 2013-11-29 | Mei Pharma Inc | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| KR102131612B1 (ko) | 2011-09-02 | 2020-07-08 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| EP2760845B1 (en) | 2011-09-27 | 2016-11-16 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| US20150011569A1 (en) * | 2011-12-15 | 2015-01-08 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF |
| ES2661510T3 (es) | 2011-12-15 | 2018-04-02 | Novartis Ag | Uso de inhibidores de la actividad o función de PI3K |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| UY34893A (es) | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | Derivados de azaindol |
| JP6125663B2 (ja) | 2012-12-21 | 2017-05-10 | ギリアード カリストガ エルエルシー | ホスファチジルイノシトール３−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン |
| NZ708870A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| UY35332A (es) | 2013-02-15 | 2014-11-28 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
| JP6417338B2 (ja) | 2013-02-19 | 2018-11-07 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| HK1223911A1 (zh) | 2013-06-14 | 2017-08-11 | Gilead Sciences, Inc. | 磷脂醯肌醇3-激酶抑制剂 |
| BR112016003019A2 (pt) * | 2013-08-13 | 2017-09-12 | Univ Illinois | composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase |
| EA036942B1 (ru) | 2013-11-11 | 2021-01-18 | Эмджен Инк. | Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза |
| TW201620904A (zh) | 2014-01-09 | 2016-06-16 | 武田藥品工業有限公司 | 氮雜吲哚衍生物 |
| WO2015106014A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| KR20170082490A (ko) | 2014-07-04 | 2017-07-14 | 루핀 리미티드 | Pi3k 억제제로서 퀴놀리지논 유도체 |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| CN105936635B (zh) * | 2015-03-06 | 2019-06-21 | 南京圣和药业股份有限公司 | 作为磷脂酰肌醇3-激酶δ抑制剂的化合物及其应用 |
| CN106008479B (zh) * | 2015-03-06 | 2020-01-10 | 南京圣和药业股份有限公司 | 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用 |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2017101829A1 (zh) * | 2015-12-16 | 2017-06-22 | 辰欣药业股份有限公司 | 吡啶并[1,2-a]嘧啶酮类似物的晶型及其制备方法和中间体 |
| WO2017103825A1 (en) | 2015-12-18 | 2017-06-22 | Lupin Limited | Quinolizinone derivatives as pi3k inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN107793397B (zh) * | 2016-09-06 | 2022-04-26 | 南京圣和药业股份有限公司 | 取代的嘧啶类pi3k抑制剂的光学异构体及其应用 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| CN108017641B (zh) * | 2016-11-02 | 2021-01-05 | 深圳铂立健医药有限公司 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP3630118A4 (en) | 2017-05-23 | 2021-03-31 | MEI Pharma, Inc. | COMBINATION THERAPY |
| CN111212643A (zh) | 2017-08-14 | 2020-05-29 | 梅制药公司 | 联合疗法 |
| ES2985118T3 (es) | 2017-09-08 | 2024-11-04 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| EP3788038B1 (en) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| EP3807276B1 (en) | 2018-06-12 | 2025-12-10 | Amgen Inc. | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| JP2021535907A (ja) * | 2018-08-21 | 2021-12-23 | 南京明徳新薬研発有限公司 | ピラゾロピリミジン誘導体及びそのｐｉ３ｋ抑制剤とする適用 |
| JP7408635B2 (ja) | 2018-08-31 | 2024-01-05 | アムジエン・インコーポレーテツド | Ｍｄｍ２阻害剤を調製する方法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| KR20250159270A (ko) | 2019-05-21 | 2025-11-10 | 암젠 인크 | 고체 상태 형태 |
| WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| MX2022006370A (es) | 2019-11-25 | 2022-09-07 | Amgen Inc | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso. |
| US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
| US20230132982A1 (en) * | 2020-02-10 | 2023-05-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma |
| WO2021164789A1 (zh) * | 2020-02-21 | 2021-08-26 | 南京明德新药研发有限公司 | 一种吡唑并嘧啶类化合物的晶型及其应用 |
| EP4149944A4 (en) * | 2020-05-16 | 2024-07-03 | Fochon Biosciences, Ltd. | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS |
| WO2025079605A1 (ja) * | 2023-10-11 | 2025-04-17 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
| US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| NZ522076A (en) * | 2000-04-25 | 2005-08-26 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| DE602006015658D1 (de) * | 2005-06-27 | 2010-09-02 | Amgen Inc | Entzündungshemmende arylnitrilverbindungen |
| AU2008231384B2 (en) * | 2007-03-23 | 2011-09-15 | Amgen Inc. | Heterocyclic compounds and their use |
| US7705018B2 (en) * | 2007-03-23 | 2010-04-27 | Amgen Inc. | Substituted quinolines and their uses in treatment of inflammatory and related conditions |
| DE102007016036A1 (de) | 2007-03-26 | 2008-10-02 | PERGANDE Gesellschaft für industrielle Entstaubungstechnik mbH | Filtersystem mit metallischen Filterelementen und Anordnung zur Reinigung |
| US8367702B2 (en) | 2007-09-26 | 2013-02-05 | Astellas Pharma Inc. | Quinolone derivative |
| GB0821693D0 (en) | 2008-11-27 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
| SG176986A1 (en) | 2009-06-25 | 2012-02-28 | Amgen Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| CA2766100C (en) * | 2009-06-29 | 2018-05-22 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| JP2013514989A (ja) | 2009-12-18 | 2013-05-02 | アムジエン・インコーポレーテツド | 複素環式化合物およびその使用法 |
-
2010
- 2010-06-25 CA CA2765817A patent/CA2765817A1/en not_active Abandoned
- 2010-06-25 US US13/377,229 patent/US8754089B2/en not_active Expired - Fee Related
- 2010-06-25 AU AU2010266064A patent/AU2010266064A1/en not_active Abandoned
- 2010-06-25 MX MX2011013901A patent/MX2011013901A/es not_active Application Discontinuation
- 2010-06-25 EP EP10728551A patent/EP2445898A2/en not_active Withdrawn
- 2010-06-25 WO PCT/US2010/039931 patent/WO2010151735A2/en not_active Ceased
- 2010-06-25 JP JP2012517758A patent/JP2012531435A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8754089B2 (en) | 2014-06-17 |
| EP2445898A2 (en) | 2012-05-02 |
| AU2010266064A1 (en) | 2012-01-19 |
| WO2010151735A2 (en) | 2010-12-29 |
| WO2010151735A3 (en) | 2011-05-12 |
| JP2012531435A (ja) | 2012-12-10 |
| CA2765817A1 (en) | 2010-12-29 |
| US20120083502A1 (en) | 2012-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011013901A (es) | Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k. | |
| WO2010151737A3 (en) | Heterocyclic compounds and their uses as inhibitors of pi3 k activity | |
| WO2011123751A3 (en) | Heterocyclic compounds and their use as pi3k inhibitors | |
| WO2010151740A3 (en) | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases | |
| MX2011013666A (es) | Compuestos heterociclicos y sus usos. | |
| MX2013007261A (es) | Compuestos heterociclicos y sus usos. | |
| MX2012015135A (es) | Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. | |
| MX2009009913A (es) | Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres. | |
| MX2012015134A (es) | Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k. | |
| MX2009009968A (es) | Compuestos heterociclicos y sus usos. | |
| MX2012015143A (es) | Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta. | |
| MX2009010050A (es) | Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k). | |
| MX2012015147A (es) | Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. | |
| PH12014502246A1 (en) | Heterocyclic compounds and their uses | |
| NZ722326A (en) | Tricyclic compounds as anticancer agents | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| SG11202008696RA (en) | Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers | |
| AR090705A1 (es) | Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k) | |
| CY1114775T1 (el) | Παραγωγα 3-υποκατεστημενης κινολινης ή κινοξαλινης και η χρηση τους ως αναστολεων της 3-κινασης φωσφατιδυλινοσιτολης (ρι3κ) | |
| MX2016009624A (es) | Compuestos heterobiciclicos novedosos como agonistas del opioide kappa. | |
| IN2013CH04706A (es) | ||
| HK40042099A (en) | Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers | |
| MX2017007648A (es) | Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |